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Abstract
Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute
respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust
animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of
the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103
TCID50 SARS-CoV showed higher body temperature (2–6 d.p.i.), sneezing (5–10 d.p.i.), lesions (5–7 d.p.i.) and decreased WBC/lymphocytes
(2–5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at
14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident
with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.
© 2007 Elsevier Inc. All rights reserved.Keywords: SARS-CoV; Ferret; Animal modelIntroduction
Severe acute respiratory syndrome (SARS) is caused by the
SARS-coronavirus (SARS-CoV), a positive-sense, single-
stranded RNA virus (Drosten et al., 2003; Kuiken et al., 2003a;
Peiris et al., 2003a). Pulmonary infection with SARS-CoV can
occur in all age groups. The average mortality rate is 9.6%;
however, among the elderly the rate is 38% to 50% (Chan et al.,
2003a,b; Chiu et al., 2003; Donnelly et al., 2003; Tsui et al.,
2003). The potential for SARS-CoV outbreaks is still warranted
since palm civets (Guan et al., 2003) and bats (Li et al., 2005) have⁎ Corresponding authors. C.B. Jonsson is to be contacted at Emerging
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doi:10.1016/j.virol.2007.12.032been implicated as possible zoonotic reservoirs for SARS-CoVor
closely related SARS-like viruses.
The discovery and evaluation of effective therapeutics for
newly emergent clinical diseases such as SARS-CoV require
well-defined animal models. Several groups have reported the
use of small animal models which may reproduce some features
of SARS in humans. These small animal models, particularly
mice (Hogan et al., 2004; Roberts et al., 2005a; Wentworth
et al., 2004; Yang et al., 2004) and hamsters (Roberts et al.,
2006, 2005b), can provide experimental systems for the study of
infectivity, immunity and pathogenesis, while serving as a very
useful tools for screening of vaccines and antiviral drugs.
However, their utility in the study of the clinical progression of
disease is limited by the inherent differences between small
mammals and humans in anatomical structure, respiratory
physiology and manifestation of clinical disease. Furthermore,
FDA approval of vaccines and therapeutics for the treatment of
emerging diseases such as SARS requires demonstration of
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nonrodent. The nonhuman primate has been used as a model
for studies of clinical progression and evaluation of treatments
for SARS-CoV infection and disease pathogenesis. However,
there has been animal-to-animal variability in the level of viral
replication in the lung tissues from SARS-CoV infected African
green monkeys (McAuliffe et al., 2004), cynomolgus macaques
(Haagmans and Osterhaus, 2006; Kuiken et al., 2003b; Lawler
et al., 2006; Osterhaus et al., 2004) and rhesus macaques (Qin
et al., 2005; Rowe et al., 2004; Tang et al., 2005; Zhou et al.,
2005). Reported symptoms in SARS-CoV infected cynomolgus
macaques (Haagmans and Osterhaus, 2006; Kuiken et al.,
2003b; Lawler et al., 2006; Rowe et al., 2004) or rhesus
macaque (Li et al., 2005; Qin et al., 2005) included lethargy,
skin rash, respiratory distress, interstitial pneumonia, and
diffuse alveoli damage. Although nonhuman primate models
mimic infection and disease symptoms seen in humans, they are
very expensive and require special housing and husbandry
practices not available in most BSL3 facilities.
One alternative nonrodent model is the domestic ferret,
Mustela putorius furo. Ferrets have not been commonly used as
animal models; therefore, and the literature sources about them
are limited. However, these animals have shown great promise
in reproducing human correlates of disease for influenza. Pre-
liminary studies showed that the domestic ferret presents di-
sease symptoms and pathology similar to that observed with
SARS-CoV infected humans (Martina et al., 2003). When both
cats and ferrets infected with SARS-CoV via the intratracheal
route using high-virus titer (up to 106 TCID50 U/mL), the cats
showed no clinical symptoms except shedding virus, whereas
the ferrets showed classical symptoms of SARS, including
death in some cases, in addition to shedding virus (Martina
et al., 2003). These studies suggested that the ferret could be
developed into a model for preclinical evaluation of efficacy for
SARS-CoV therapeutics.
The overall objective of our efforts was to develop and
characterize the ferret model for permissive SARS-CoV infection
and disease following intensive optimization of the dosing and
various endpoints. Herein, we report the validation of themodel in
an infection and challenge over 58 days. The study validated
standard health indicator endpoints that allow comparisons to
clinical manifestation of SARS-CoV in human patients. These
included: clinical findings, temperature, mean body weight,
hematology and clinical chemistry parameters, gross pathologyTable 1
Study design and key clinical observations
Group Day 0 Day 29
1 (mock-infected) SFM None
2 (SARS-CoV infected) SARS-CoV (103 TCID50) None
3 (mock-challenged) SFM SFM
4 (SARS-CoV challenged) SARS-CoV (103 TCID50) SARS-CoV (10
3 TCID
aThe indicated clinical observations were expressed as the number of observations/t
bOne ferret in this group was euthanized early after developing a moribund state.
SFM: Serum Free media (DMEM).and histopathology, and virological and immunological assess-
ments. This model will provide insight into understanding many
of the underlying features of SARS disease in humans and pro-
mote the evaluation of promising therapeutics and vaccines.
Results
Study design
Ferrets were divided randomly into four groups, mock-in-
fected, SARS-CoV infected, mock-challenged, and SARS-CoV
challenged (Table 1). The dose of SARS-CoV chosen for these
studies was based upon several smaller studies in ferrets with
different challenge doses ranging from 103 to 107 TCID50/mL
(Fig. 1). In general, the lower dose of virus produced more
reproducible results. The lower dose of virus showed less vari-
ation in the level of viral infection in the lung. Specifically, the
higher dose, 107 TCID50/mL, showed minimal infection of the
ferret nasal turbinates (NT) and variability in the lung. The 103
TCID50/mL dose provided the highest infection and reprodu-
cibility in NT and lung tissues (Fig. 1).
On 0 d.p.i., ferrets in the mock-infected group (Group 1, 18
ferrets) were inoculated intranasally with serum-free medium
without virus, and ferrets in the SARS-CoV infected group
(Group 2, 42 ferrets) were inoculated intranasally with 103
TCID50 SARS-CoV diluted in serum-free medium. On 29 d.p.i.,
nine ferrets from Group 1 were mock-challenged with serum-
free medium (Group 3), and eighteen ferrets from Group 2 were
challenged with 103 TCID50 SARS-CoV (Group 4). Ferrets
were observed twice daily, with detailed recording of phar-
macological and toxicological signs and symptoms, including
nature, onset, severity, and duration of all gross or visible
changes (including but not limited to abnormal circulatory,
respiratory, excretory, behavioral, and neurological signs and
symptoms). In addition, an activity score (0=alert and playful,
1=alert but playful only when stimulated, 2=alert but not
playful when stimulated, and 3=neither alert nor playful when
stimulated) was obtained each time the ferrets were observed. At
predetermined time points, post-inoculation as described in the
Materials and Methods, ferrets (three ferrets from Group 1, 3, 4,
and four from Group 2) were euthanized, and specimens were
collected for analyses of viral load (TCID50) and neutralization
antibody, viral RNA by RT-PCR, changes in cytology (immu-
nohistochemistry and histopathology) and changes in clinicalNumber
of
animals
Sneezing Diarrhea Mortality
and
morbidity
bday 29 Nday 29 bday 29 Nday 29
18 0/18a None 1/18 None 0/18
42 17/42 None 5/42 None 0/42
9 None 0/9 None 1/9 0/9
50) 18 None 0/18 None 5/18 1/18
b
otal sample number.
Fig. 1. Titers of SARS-CoV in nasal turbinate (NT) and lung samples from
ferrets infected at different doses. Bar graphs show the mean titer of virus
detected by TCID50 assays on Vero E6 cell monolayer as described in the
Materials and Methods. Virus titers are shown for lung and nasal turbinates at
three different doses of virus in ferrets: 103, 105 and 107.
153Y.-K. Chu et al. / Virology 374 (2008) 151–163pathology (chemistry and hematology) as described in Materials
and Methods.
Clinical observations
Subcutaneous body temperatures and clinical observations
were obtained twice daily. Graphs of temperature profiles
(Fig. 2) depict mean temperatures for the four groups—mock-
infected (Group 1), SARS-CoV infected (Group 2), mock-
challenged (Group 3) and SARS-CoV challenged (Group 4).
Overall, the mean temperatures in all four groups were within
the normal range for ferrets, between 35 °C and 39.4 °C,
inclusively. Three ferrets in Group 1 had abnormal low body
temperature from 1 to 7 d.p.i. In the SARS-CoV infected group
(Group 2), temperature increases were evident from 2–7 d.p.i.,
and statistical analysis showed that there were significant
temperature increases on 2 and 6 d.p.i. (P value 0.0500 and
0.0157, respectively) as compared to temperatures in mock-
infected ferrets (Group 1). Significantly lower temperatures in
SARS-CoV infected ferrets were observed on 16 and 24 d.p.i.
The interpretation of these findings is unclear. These resultsFig. 2. Daily temperature (°C) fluctuation in mock-infected and SARS-CoV infected
designated and number of animals for each group were indicated in Table 1.support body temperature as a useful marker in assessing
SARS-CoV infection in ferrets.
All animals were alert and playful (activity score=0) with
the exception of one ferret in Group 4, which will be discussed
later. The clinical observations focused on sneezing, fever,
diarrhea, mortality and morbidity (Table 1). While ferrets in the
mock-infected Group 1 did not show any sneezing, 17 ferrets
among 42 SARS-CoV infected ferrets in Group 2 did. Sneezing
was observed as early as 3 d.p.i. and as late as 10 d.p.i. of the
study, with most of the sneezing observed between 5 and 10 d.p.
i. One ferret among 42 infected ferrets showed both sneezing
and ocular discharge, but these two symptoms occurred at
different times. No sneezing was observed among 18 SARS-
CoV challenged ferrets (Group 4) or the mock-challenged fer-
rets (Group 3) (Table 1).
Diarrhea was also observed in some ferrets, both in the
SARS-CoV infected and mock-infected groups. One ferret in
Group 1 had diarrhea at 26 d.p.i., and one ferret in Group 3
showed diarrhea at 15–16 d.p.i. However, five out of 42 ferrets
in Group 2 (Table 1) had diarrhea. After challenge, five out of
18 ferrets in Group 4 had diarrhea (Table 1), three showing
diarrhea before challenge.
Mortality and morbidity of ferrets were examined twice per
day (morning and afternoon) on each day of the study including:
identifying dead, weak, or moribund animals; and documenting
the onset of any abnormal clinical signs. Moribund animals were
defined as those exhibiting: seizures, severe depression, respira-
tory distress, severe dyspnea (difficult or labored breathing),
recumbence and weakness, unresponsiveness to touch and ex-
ternal stimuli, 20% or greater loss in body weight, body tem-
perature below 36.1 °C (indicative of shock), and total anorexia
with duration longer than 48 h. Only one ferret from Group 4 had
to be euthanized early after developing a moribund state with
symptoms including diarrhea, dehydration, hypothermia, and
decreased food intake. The disease in this animal was unrelated to
SARS-CoVinfection as determined by an absence of virus or viral
RNAwhich will be discussed in later sections.
Body weight was taken prior to mock or viral infection/
challenge and at necropsy for each group. No significant changeferrets. Significantly higher or lower temperatures are marked with “ ⁎ ”. Group
Fig. 3. SARS-CoV titer in different tissues and body fluids collected from mock and SARS-CoV infected ferrets. Line graphs show the mean titer of virus detected by
TCID50 assays on Vero E6 cell monolayer as described in the Materials and Methods. Virus titers are shown for (A) Lung, (B) Nasal Turbinates, (C) Nasal swabs, and
(D) Pharyngeal swabs. Symbols: closed square (virus-infected) and open circle (mock-infected); error bars indicate standard error. Dot line indicates that one or two
data points were not available as indicated in the study designed. n=3 in Group 1, 3, 4, and n=4 in Group 2. Symbols: closed square (virus infected) and open circle
(mock-infected).
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Table 2
SARS-CoV Toronto 2 vRNA detected in ferret swabs and tissues
SARS-CoV
Infected
Group 2 (d.p.i.)
NS PS RS T
(u)
T
(l)
GI
(C)
GI
(D)
NT LUNG LIVER
2 4/4 4/4 0/4 0/4 0/4 0/4 0/4 3/4 2/4 0/4
3 4/4 4/4 0/4 0/4 0/4 0/4 0/4 3/4 1/4 0/4
5 4/4 4/4 1/4 0/4 0/4 0/4 0/4 4/4 4/4 0/4
7 3/4 3/4 0/4 0/4 0/4 0/4 0/4 4/4 4/4 0/4
14 0/4 0/4 0/4 0/4 0/4 0/4 0/4 1/4 0/4 0/4
28 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4
SARS-CoV
Challenged
Group 4 (d.p.i.)
31 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
32 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
34 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
36 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
43 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
57 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Table shows the number of positive per total sample number analyzed in indicat-
ed swab and tissue homogenates. Legend: NS-Nasal Swab; PS-Pharyngeal Swab;
RS-Rectal Swab; T(u)-Trachea (upper); T(l) Trachea (lower); GI (C)-GI colon;
GI (D)-GI duodenum; NT-Nasal Turbinates.
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The respective weights for whole lung, liver and heart were
obtained at necropsy for all ferrets. A ratio of group mean organ
weight to group mean body weight (mean organ wt/mean body
wt) was calculated for all groups. The mean lung weight to body
weight showed an increase above background in Group 2 ferrets
sacrificed on study 7 d.p.i. (data not shown); however, such
increases were not statistically significant ( p=0.108). There
were no remarkable differences in mean liver and heart weight
(data not shown) between Group 1 and Group 2.
SARS-CoV titer in tissues, nasal, pharyngeal and fecal samples
Viral burdens in the lung, nasal turbinates, upper and lower
trachea, duodenum, liver and colon were determined by TCID50.
Significant viral titers were detected in lung and nasal turbinatesFig. 4. Reciprocal neutralizing antibody titers from mock or SARS-CoV infected ferr
Group 1, 3, 4, and n=4 in Group 2. Symbols: closed square (virus infected) and optissue from infected animals (Fig. 3). Viral titers in lung tissue
were 1 log10 above the background level (10
3 TCID50 U/mL) at
2 d.p.i., and increased to 3 log10 above the background level
(105 TCID50 U/mL) at 5 d.p.i. (Fig. 3A). Viral titers in nasal
turbinates increased to 5 log10 above background level
(107 TCID50 U/mL) at 2 d.p.i., and decreased slightly at 3 and
5 d.p.i. prior to dropping on day 7 p.i., (106 TCID50 U/mL)
(Fig. 3B). Samples from the liver lysates had high background
noise levels, which made the measurement of viral titers difficult.
However, virus titers in liver samples were below background
levels (data not shown). Similarly, the duodenum, upper trachea
and lower trachea had no detectable virus titers (data not shown).
Virus shedding was measured in nasal, pharyngeal and rectal
samples. Significant viral titers were detected in nasal and
pharyngeal fluids of infected animals (Figs. 3C, D) with 1 to 4
logs above the background level (103 to 106 TCID50/mL). Of
note, viral titers post challenge (29 to 57 d.p.i) were generally
near or below background (Figs. 3A–D). This suggests that the
virus was unable to re-establish an infection in previously
infected animals.
Detection of viral RNA by RT-PCR
Total RNA was isolated from tissue homogenates and fluid
and excreta swab samples, and analyzed using primers specific
for the SARS-CoV nucleocapsid gene. In Group 2, viral RNA
was detected in nasal and pharyngeal swabs, nasal turbinates and
lung homogenates in the majority of the ferrets from 2 to 7 d.p.i.
(Table 2). Overall, the viral RNA levels correlated with viral
TCID50 titers for individual animals. The rectal swab on day five
from a single ferret was positive for viral RNA and correlated
with the TCID50 result for this animal. On 14 d.p.i., one ferret
remained RT-PCR positive; the virus titer for this animal was
below the background level. In Groups 1, 3 and 4, no viral RNA
was detected in any of the body fluid or tissue samples (Table 2).
As mentioned previously, one ferret in Group 4 exhibited
serious health conditions during the course of the study. This
ferret had diarrhea from 34 to 48 d.p.i. of the study. On 48 d.p.i.,
this ferret exhibited dehydration, hypothermia and decreased food
intake and was declared as moribund and euthanized. Neitherets. Mean antibody titers from three or four ferrets per group are shown. n=3 in
en circle (mock-infected). Error bars indicate standard errors.
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liver, lung, and lower trachea samples from this ferret; thus, illness
was not from SARS-CoV infection.
Neutralization antibody to SARS-CoV
The levels of neutralizing antibody to SARS-CoV were
evaluated for all four groups (Fig. 4). No neutralizing antibodies
were detected in Groups 1 and 3. In Group 2, neutralizing
antibodies increased from 7 d.p.i., reaching a peak titer of 820 U
on 14 d.p.i. and decreased slightly to 720 U on 29 d.p.i. before
challenge (Fig. 4). The temporal course of neutralizingFig. 5. Representative histologic lesions in lung sections taken on 7 d.p.i. from
bronchiolar infiltrates with extension into adjacent alveoli (small arrows). (B) Lympho
type II pneumocyte hyperplasia (large arrow). (C) Lymphohistiocytic infiltrates in th
bronchiolar epithelium (arrowhead). (D) Normal lung from a mock-infected ferret. (
bronchoalveolar junction and small blood vessel from a mock-infected ferret.antibodies correlated with decreasing viral burden in the lung,
nasal turbinates, nasal and pharyngeal swab samples at 7 d.p.i.
Following SARS-CoV challenge (29 d.p.i.), an anamnestic
response was evident for all Group 4 animals with an abrupt
increment of neutralizing antibodies to 1300 U, the peak data
point for the study. The titers stayed high for about two weeks,
and then fell to 400 U by 57 d.p.i.
Histopathology
Sections of lung lobes (left cranial, left caudal, right cranial and
right middle), trachea, colon, duodenum, and liver were stainedSARS-CoV (A–C) and mock-infected (D–F) ferrets. (A) Lymphohistiocytic
histiocytic infiltrates in alveolar septae and associated alveoli (small arrow), with
e walls of pulmonary vessels and bronchioles (small arrow), with hyperplasia of
E) Normal alveolar septae and alveoli from a mock-infected ferret. (F) Normal
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direct microscopical observation. Lesions were graded subjec-
tively and blindly on a scale of 1 to 4 (1 = minimal, 2 = mild, 3 =
moderate, 4 = marked), with distribution modifiers of focal (F),
multifocal (M) and diffuse (D).
Lesions related to SARS-CoV infection were identified in
the lungs of Group 2 ferrets on 5 and 7 d.p.i. with more severe
lesions evident at 7 d.p.i.(Fig. 5A), when compared with the
lung lesions from Group 1 animals (Fig. 5D). The primaryFig. 6. Clinical hematology of blood samples collected from mock and SARS-CoV in
ferrets. Mock and SARS-CoV infected blood samples were compared with the bas
(B) Lymphocytes, and (C) Neutrophils. Dot line indicates that one or two data points
n=4 in Group 2. Symbols: closed square (virus infected) and open circle (mock-infSARS-related lesion identified in Group 2 animals consisted of
lymphohistiocytic bronchointerstitial pneumonia (Fig. 5B). In
addition, there was a marked increase in the number of lympho-
cytes and macrophages associated with the pulmonary vascu-
lature and the connective tissue surrounding conducting airways
(Fig. 5C), which was not observed in lungs in Group 1 (Fig. 5F).
Severely affected animals developed mild to moderate involve-
ment of bronchi, with luminal accumulation of mucus and
neutrophils. A few infected animals also had small collectionsfected ferrets. A baseline was obtained from 47 pre-study sera obtained from 26
eline. Three of the parameters analyzed are presented: (A) White blood cells,
were not available as indicated in the study designed. n=3 in Group 1, 3, 4, and
ected). Error bars indicate standard errors.
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veolar junctions. Histologic lesions related to SARS-CoV were
not detected among challenged ferrets (results not shown).
Lesions present in many animals from both SARS-CoV
exposed and unexposed groups, interpreted to be background
lesions unrelated to SARS-CoV exposure, consisted of conges-
tion, minimal to mild peribronchovascular accumulations of
lymphocytes, and minimal to mild bronchiolitis.
Clinical chemistry
Baseline values for different clinical chemistry parameters
were measured for 60 pre-study serum samples obtained from
30 ferrets. The samples were analyzed for levels of alanine
aminotransferase, alkaline phosphatase, albumin, lactate dehy-
drogenase, aspartate aminotransferase, total bilirubin, blood
urea nitrogen, calcium, chloride, cholesterol, creatine kinase,
creatinine, gamma glutamyl transferase, glucose, phosphorus,
potassium, sodium, total protein, triglyceride, globulin, and
albumin/globulin. The group mean values were compared to
identify any trends suggestive of SARS-CoV infection. The
values from the infected ferrets were compared with the base-
line to examine if there was a significant difference. The lactate
dehydrogenase levels in serum of Group 2 were significantly
higher on 2, 3 and 5 d.p.i. than Group 1 (data not shown) and
appear to be a disease marker worthy of further investigation.
Although gamma glutamyl transferase (GGT) was expressed
in most of the ferrets, the levels in Group 2 ferrets were gene-
rally higher. The baseline value for GGT was negative (very
low); hence, it was not included in the comparison. Serum
levels of GGT showed some differences between Groups 1 and
2, but they were not significant (results not shown). However,
the small sample size (n=3 or n=4) may have been a factor in
the outcome observed in this study; therefore, levels of GGT
might warrant further investigation. All other parameters (re-
sults not shown), were not significantly different between mock
and infected groups (results not shown).
Generally speaking, the major symptom from Group 2 ferrets
was dehydration. While dehydration might be a good disease
marker, cautions need to be taken to interpret all the clinical
chemistry observations.
Hematology
Baseline values for the hematology parameters, including
white blood cell count, red blood cell count, hemoglobin con-
centration, hematocrit, mean corpuscular volume, mean corpus-
cular hemoglobin, mean corpuscular hemoglobin concentration,
neutrophils, lymphocytes, monocytes, eosinophils, basophils,
leucocytes, and reticulolocytes were obtained from 47 pre-study
blood samples obtained from 26 ferrets. Group 1–4 mean values
and the predetermined baseline values (prior to day 0) were
plotted on graphs to identify any trends that correlated with
SARS-CoV infection (Fig. 6). Values from SARS-CoV infected
ferrets (Groups 2 and 4) were compared with mock-infected or
challenged (Groups 1 and 3)with the baseline. The levels of white
blood cells were significantly lower on 2 d.p.i. (Fig. 6A). Group 2blood levels of lymphocytes (Fig. 6B)were lower on 2–5 d.p.i and
marginally higher on 36 d.p.i. as compared to the baseline value.
The level of neutrophils in Group 2 (Fig. 6C) were generally
higher than the baseline but were not significant. Group 4 showed
levels similar to baseline for all measurements (Figs. 6A–C). All
other hematology parameters were not significantly different from
the baseline values; however, this may need further confirmation
in future experiments using a larger sample size.
Discussion
Patients infected with SARS-CoV show general influenza-
like symptoms, fever, headache, malaise, cough, loss of appe-
tite, diarrhea and myalgia (Bitnun et al., 2003; Booth et al.,
2003; Chiu et al., 2003; Drosten et al., 2003; Kuiken et al.,
2003b; Leung et al., 2003; Peiris et al., 2003b). Older adult
patients infected with SARS-CoVoften develop a severe febrile
pneumonia [for example see (Peiris et al., 2003b)]. In contrast to
SARS in adults, SARS in young children tends to be a relatively
mild disease. Adolescents can experience significant respiratory
disease similar to adults, but younger children generally do not
(Bitnun et al., 2003). Symptoms such as myalgias, chills, and
headache, which are common in adults, are usually absent in
children (Leung et al., 2003; Wong and Fok, 2004). Children
have a shorter course of illness, and generally do not develop
significant pulmonary disease requiring assisted ventilation
(Bitnun et al., 2003; Chiu et al., 2003; Hon et al., 2003; Leung
et al., 2003, 2004; Puthucheary et al., 2004). Adults and children
appear to have similar levels of SARS-CoV viremia associated
with infection, implying that levels of viral replication are
similar in both groups (Ng et al., 2003, 2004). Adults with SARS
have significantly increased serum levels of inflammatory
cytokines and chemokines (Hon et al., 2003; Huang et al.,
2005; Wong et al., 2004; Zhang et al., 2004). Activation of
inflammatory cytokines in children with SARS may be less
dramatic (Ng et al., 2003). Thus, immune response may account
for variations in SARS severity between age groups. Develop-
ment of animal models that reflect these variations in the human
population is challenging. However, we noted several para-
meters common in many of the cases such as temperature,
diarrhea, viremia and neutralizing antibody; hence, we sought to
discover an animal model that displays these symptoms.
The ferret belongs to the order Carnivora, family Musteli-
dae, and is related to mink, otters, and weasels. The domestic
(European) ferret (Mustela putorius furo) has been domesticated
for thousands of years (Ball, 2006). Ferrets have some unique
applications including study of human influenza (Renegar, 1992;
Smith and Sweet, 1988), and peptic ulcer disease (Del Giudice
et al., 2001; Fox et al., 1997). In addition to many basic research
applications, ferrets are under active investigation as a nonrodent
model in drug development (Fox et al., 1997). More recently, the
ferret was explored as a model for SARS; however, the few
reports in the literature show apparently conflicting data with
regard to infection and pathogenesis of ferret with SARS-CoV,
primarily because of differences in study designs, age of animals,
and endpoints examined. While Martina et al. have shown that
ferrets support SARS-CoV replication and develop pulmonary
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ferrets remain asymptomatic in the presence of SARS-CoV
replication (Weingartl et al., 2004). Herein we have demonstrated
that the ferret is a suitable model for permissive SARS-CoV
infection, which shows clinically relevant indicators of illness and
disease progression. Clinically, we showed temperature increase
and sneezing in challenged animals. Fever is one of the disease
markers for SARS-CoV infection in humans (Bitnun et al., 2003;
Booth et al., 2003; Ksiazek et al., 2003; Kuiken et al., 2003b; Tsui
et al., 2003; Wong and Fok, 2004), and in ferrets a temperature
increase was significant from 2–6 d.p.i. Sneezing was consis-
tently observed in ferrets from 5–10 d.p.i. (Table 1) but was not
observed in mock-infected or challenged ferrets.
In general, the SARS-CoV dose used in the animal models
reported to date range from 103–106 TCID50 by intranasal
infection. The dose used in this study (103) reached similar virus
titers used at the higher doses reported. We detected significant
levels of SARS-CoV in lung, nasal turbinates, nasal swab and
pharyngeal swab samples from infected animals. Virus replication
could be detected from 2–7 d.p.i., and the highest peak of virus
replication was detected in the upper respiratory region (nasal
turbinate) followed by the lower respiratory region (lung). We
detected viral RNA by RT-PCR in the nasal and pharyngeal swabs
through 7 d.p.i. In general, most animal models show peak days of
viral RNA in the lung and nasal turbinate samples from 2 to 7 d.p.i.
Ferrets infected with 103 or 104 TCID50, sustain viral replication at
106 TCID50/mL at 4 d.p.i. (Martina et al., 2003), while ter Meulen
et al. show a peak day of infection at 7 d.p.i., in the lung (terMeulen
et al., 2004). Both studies used the SARS-CoV strain HKU-39849.
Studies reported by Weingartl et al. and Czub et al., however,
showed much longer persistence of viral RNA in lung, pharyngeal
and feces samples (Czub et al., 2005;Weingartl et al., 2004). One of
themore promisingmodels for SARS-CoVpathogenesis in rodents
is the Golden Syrian Hamster, which shows sustained viral
replication in the nasal turbinates and lungs (Roberts et al., 2007).
After intranasal inoculation with 103 TCID50 of SARS-CoV, peak
viral replication in the lungs occurred at 3 d.p.i. and was cleared by
7 d.p.i; however, viral titers in nasal turbinates were about 10 to 100
folds lower than in lungs and detected through 14 d.p.i.(Roberts et
al., 2005b). In our ferret study, viral titers in the nasal turbinates
were about 100- to 1000-fold higher (five logs above background)
than in the lungs. Virus was also detected in the spleen and liver of
the hamster (Roberts et al., 2005b); in contrast, we did not detect
virus or viral RNA in the liver of the ferret.
The primary SARS-CoV infection-related lesion in the ferret
model was lymphohistiocytic bronchointerstitial pneumonia,
which was observed on days 5 and 7 after exposure. In addition,
there was a marked increase in the number of lymphocytes and
macrophages associated with the pulmonary vasculature and the
connective tissue surrounding conducting airways. This kind of
pathological presentation has also been observed in SARS-CoV
infected nonhuman primates and correlated with the milder
syndrome of SARS-CoV infection in human (Kuiken et al.,
2004; Lawler et al., 2006; Qin et al., 2005). A relative increase
in lung weight, although not significant due to the small sample
size, was observed at 7 d.p.i. in infected group, this result
corresponded to the period when sneezing was observed.The occurrence of immune pathology has been a concern in
the development of an effective vaccine for SARS (Czub et al.,
2005). Disease-enhancing antibodies may be induced after
natural viral infections as demonstrated with dengue and feline
coronaviruses (Green and Rothman, 2006; Smith and Sweet,
1988; Olsen et al., 1992 ). Antibodies to the spike protein of the
feline coronaviruses are involved in antibody-dependent enhan-
cement of infection. Passive transfer of sera from SARS-CoV
infected mice provided protection against subsequent challenge
(Subbarao et al., 2004). The absence of histopathological change
in the lungs of the challenge group is an indication of the absence
of immune pathology in ferrets. The increase in neutralizing
antibodies from 7 to 14 d.p.i. correlated with a decrease in viral
burden observed in the lung, nasal turbinates, nasal swab and
pharyngeal swab samples. Upon challenge one month after
primary infection, a significant increase of antibody titers was
observed and the antibody titer was higher than that seen after
primary infection. The boost in antibody titer may have con-
tributed to the lower viral burden observed after the challenge.
Therefore, neutralizing antibodies can be considered as a cor-
relate of protection in SARS-CoV infected animals. In summary,
the SARS ferret model and the endpoints identified herein
provide a platform for investigations into the immune response
and pathogenesis, as well as the evaluation of the efficacy of
potential antiviral drugs and vaccines for SARS-CoV disease.
Materials and methods
Virus and cells
SARS-CoV, strain Toronto-2, was provided by Dr. Heinz
Feldman at the University of Manitoba. SARS-CoV seed stocks
with a titer of 107 TCID50 U/mL were propagated in Vero E6
cells (ATCC, VERO C1008, CRL 1586). The seed stocks were
diluted to the designated titer and used for SARS-CoV TCID50
and neutralizing antibody assays.
Ferrets
Male ferrets,Mustela putorius furo, 36–45 weeks of age, were
purchased fromTriple F Farms (Sayre, PA). Ferrets were screened
by Triple F Farms for a standard panel of pathogens and at
Southern Research Institute for influenza viruses using a standard
hemagglutinin assay (Stephenson et al., 2004). Only influenza-
free ferrets were used for this study. The pre-study weights of the
ferrets ranged from 1 kg to 1.5 kg. The ferrets were uniquely
identified by ear tags and subcutaneous transponders (IPTT-300;
Biomedic Data Systems Inc, Seaford, Delaware) which were also
utilized to measure body temperature. Animal housing and all the
animal manipulations were approved by the Animal Care Com-
mittee and met the Animal Care guidelines.
SARS-CoV ferret model study design
All animal work was performed in an ABSL3 containment
facility. Ferrets were divided randomly into four groups based
upon SARS-CoV infection, mock infection, and challenge with
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four ferrets (Group 1) were inoculated intranasally with serum-
free medium only, and forty-two (Group 2) with SARS-CoV
(103 TCID50/mL) diluted in medium. On 29 d.p.i., nine ferrets
(Group 3) were inoculated with serum-free medium, and eigh-
teen ferrets (Group 4) were challenged and inoculated with
SARS-CoV (103 TCID50) diluted in medium. Prior to instil-
lation of mock or virus inoculums, all ferrets were anesthetized,
and 1 mL of the inoculum was administered intranasally by
drop-wise delivery of 500 μL per nare. Ferrets were observed
twice daily, with detailed recording of clinical signs, symptoms,
morbidity and mortality including nature, onset, severity, and
duration of all gross or visible changes. For the mock-infected
group (Groups 1 and 3), three ferrets were sequentially sacri-
ficed on 2, 7, 14, 28, 31, 36, 57 d.p.i (after the first challenge).
For SARS-CoV infected (Group 2) and challenged group
(Group 4), four (Group 2) and three (Group 4) ferrets were
sequentially sacrificed on 2, 3, 5, 7, 14, 28, 31, 32, 34, 36, 43, 57
d.p.i (after the first challenge). Tissue specimens, including lung,
nasal turbinates, upper and lower trachea, duodenum, liver and
colon; different swab samples, including nasal swab, pharyngeal
swab and rectal swab, as well as blood, were collected for
various pathological, virological, and immunological tests.
Determination of tissue viral burden
Tissue samples were homogenized to a final 10% (wt/v)
suspension in complete DMEM, clarified by low speed centri-
fugation at 4500 ×g for 30 min at 4 °C, and virus titers were
determined in Vero E6 cell monolayers grown in 96-well plat-
es. Vero E6 cells were seeded (20,000/well) in a 96-well plate
and incubated overnight at 37 °C in a CO2 incubator. 100 μL of
10-fold serially diluted 10% tissue suspension was added to each
well in quadruplicate format. Plates were incubated in a CO2
incubator at 37 °C for 3 days, after which cytopathic effect (CPE)
was observed microscopically at 40× magnification. Virus titers
were expressed as TCID50 units per gram of tissue, with a lower
limit of detection of 102 TCID50 U/g.
Viral neutralization assay
For the neutralization test, serum samples were two-fold
diluted from an initial 1:5 to a final dilution of 1:320, mixed
with 60 μL of 2000 TCID50/mL of virus and incubated over-
night at 4 °C. This was performed in duplicate. The following
morning, 100 μL of virus-serum mixture was inoculated to Vero
E6 cells which were seeded at 20,000/well as previously pre-
pared. The inoculated plates were incubated in a CO2 incubator
at 37 °C for 3 days, after which CPE of the virus was observed
microscopically at 40× magnification.
RNA extraction
Total RNA was extracted from experimental samples, tissue
and fluid homogenate suspensions as described for TRIzol LS
Reagent (Invitrogen; Carlsbad, CA) according to the manufac-
turer's instructions. Dried RNA pellets were resuspended in35 μL of nuclease-free water and stored at −80 °C before RT-
PCR amplification was carried out. The RNAwas measured for
quantity and quality using the Experion Automated Electro-
phoresis System (Bio-Rad). All RNA extractions were per-
formed in a BSL 2+ Laboratory.
RT-PCR for SARS-CoV
Reverse transcription reactions were performed using Super-
script III-Reverse Transcriptase (Invitrogen; Carlsbad, CA) with
random primers. Each reaction mixture included 100 ng of
randomprimers, 0.1 to 1.0μg of total RNA from each sample, and
1 μL of dNTP's (10 mM). The mixture was heated to 65 °C for
5 min and placed on ice for 1 min. The following components
were added per reaction: 4 μL 5× first strand buffer; 1 μL DTT
(0.1 M); 1 μL RNase OUT; Recombinant RNase Inhibitor; and
1 μL of Superscript III RT (200 U/μL) (Invitrogen). The RT
reactions were carried out at 25 °C for 5 min, followed by
incubation at 50 °C for 60 min and inactivation of the enzyme at
70 °C for 15 min. To remove RNA in the above mixture, 1 μL of
E. coli RNase H was added and incubated at 37 °C for another
20 min. All cDNA samples were stored at −20 °C until used for
PCR and/or Quantitative Real-Time PCR. For most experimental
samples and the positive control (SARS-CoV, Toronto-2 Strain),
duplicate cDNA samples were made for each total RNA sample.
Primers fromSARS-CoV,Tor-2 strainwere used to quantify the
amount of viral RNA present in RT samples. The primers are
specific for the nucleocapsid (N) gene of the SARS-CoV (Gen-
Bank accession # AY274119). The primers sequences used for the
PCR detection were as follows: SARS-N-forward 5′-ACC AGA
ATG GAG GAC GCA ATG-3′ and SARS-N-reverse 5′-GCT
GTGAACCAAGACGCAGTATTAT-3′ (Applied Biosystems;
Foster City, CA). A 2–5 μL of each cDNA sample was amplified
in a 50 μL reaction that contained 5 μL of 10× High Fidelity PCR
Buffer (Invitrogen), 1μLof each of the 10 µM forward and reverse
primers, final 1.5 mM of MgSO4 (50 mM), final 0.2 mM of the
dNTP (10 mM) and 2 Units of the HI Fidelity Taq Polymerase
(5 U/μL). PCR optimized reactions were incubated at 94 °C for
2 min followed by 30 cycles at 94 °C for 30 s, 56 °C for 30 s, and
68 °C for 30 s and maintained at final 4 °C. All reactions were set
up in thin shell 0.2 mL PCR tubes and all reactions were run on a
MJ Research Thermal Cycler (Bio-Rad). The PCR products were
electrophoresed in a 4% NuSieve agarose gel (Invitrogen).
Clinical chemistry
At necropsy, 1.5 mL whole blood was collected into plastic
Gold-top BD Vacutainer SST® Gel tubes with Hemogard™
Closure (3.5 mL draw; BD, Franklin Lakes, NJ). Blood was
allowed to clot and then centrifuged for a minimum of 10 min at
1300 ×g. Serum was held at 4 to 8 °C until analyzed. Serum
samples from all ferrets were analyzed using the Hitachi
911Chemistry Analyzer. Following the manufacturer's manual,
the samples were analyzed for levels of alanine aminotransferase,
alkaline phosphatase, albumin, lactate dehydrogenase, aspartate
aminotransferase, bilirubin-total, blood urea nitrogen, calcium,
chloride, cholesterol, creatine kinase, creatinine, gamma glutamyl
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tein, triglyceride, globulin, and albumin/globulin. Baseline values
for these parameters were obtained from 60 pre-study serum
samples obtained from 30 ferrets.
Clinical hematology
At necropsy, 1.0 mL whole blood was collected into plastic
Lavender-top BD Vacutainer® tubes with Hemogard™ Closure
(2 mL draw; BD, Franklin Lakes, NJ) containing EDTA as the
anti-coagulant. Whole blood samples were kept at room tem-
perature until analyzed. Blood samples from all ferrets were
analyzed using Advia (white blood cell count, red blood cell
count, hemoglobin concentration, hematocrit, mean corpuscular
volume, mean corpuscular hemoglobin, mean corpuscular he-
moglobin concentration, neutrophils, lymphocytes, monocytes,
eosinophils, basophils, leucocytes, and reticulolocytes). Base-
line values for these parameters were obtained from 47 pre-
study blood samples obtained from 26 ferrets. Ferrets are an
unidentified species on the Advia, and Bayer protocol states that
samples were run using dog species selection. Differences in
normal erythrocytes between dogs and ferrets lead to many
ferret samples being flagged for microcytosis and/or hypochro-
masia. Dog MCV normal ranges are 58.8–71.2 fL and ferret
MCV normal ranges are 46–65 fL. Dog MCHC normal ranges
are 31.0–36.2 g/dL and ferret MCHC normal ranges are 29–
36 g/dL. However, manual smear reviews also did not suggest
substantive erythrocyte anomalies; thus, these flags may be
disregarded in this study.
Histopathology
Mock-infected or SARS-CoV infected ferrets were eutha-
nized and the trachea and lungs were removed en bloc. The left
cranial (LCr), left caudal (LCd), right cranial (RCr), and right
middle (RMi) lung lobes were inflated via a tracheal cannula
with 4% paraformaldehyde to approximate normal volume. The
inflated lungs were then immersed in 4% paraformaldehyde and
allowed to fix for a minimum of 48 h. Sections of trachea, liver,
duodenum and colon were also fixed in 4% paraformaldehyde
for subsequent histopathology. The fixed tissues were then
washed in PBS, and processed routinely for paraffin embedding.
Tissue sections (5 μm) were stained with hematoxylin and eosin
(H&E) to assess histopathological changes in response to SARS-
CoV infection. Multiple tissue sections were examined by a
veterinary pathologist. Histopathologic changes were assessed
for severity [1 (minimal), 2 (mild), 3 (moderate) and 4 (marked)]
and distribution (focal, multifocal, diffuse).
Definitions are as follows:
1) Bronchiolitis, mixed, histiocytic and granulocytic: Inflam-
mation of bronchioles characterized by accumulation of
histiocytes, eosinophils and/or neutrophils in varying
proportions in the walls of bronchioles or at the bronchio-
loalveolar junction.
2) Bronchitis, suppurative, with increased mucus and bronchial
epithelial hyperplasia: Inflammation of bronchi character-ized by transmigration of neutrophils through the bronchial
wall, luminal accumulation of neutrophils and mucus, and
variable hyperplasia of bronchial epithelium.
3) Bronchointerstitial pneumonia, mononuclear, with type II cell
hyperplasia: Inflammation of bronchioles and adjacent alveoli,
characterized by infiltrates of lymphocytes and macrophages
into the bronchiolar and alveolar septal walls and associated
alveoli, with occasional apoptotic/necrotic debris. Bronchiolar
epithelial cells vary in appearance from hypertrophied/hyper-
plastic to flattened and attenuated. Inflammation is often asso-
ciatedwithmild type II cell hyperplasia,with variable atypia and
infrequent binucleated cells.
4) Perivascular lymphoid aggregates: Accumulation of lym-
phocytes and lesser macrophages adjacent to and sometimes
cuffing pulmonary blood vessels.
5) Peribronchial lymphoid hyperplasia: Accumulation of lym-
phocytes and lesser macrophages in the bronchial and/or
bronchiolar walls and subjacent connective tissues.
6) Euthanasia artifact: Foci of poorly stained tissues with loss of
differential staining and loss of nuclear and cytoplasmic detail.
Statistical analysis
Numerical data obtained during the conduct of the study
were subjected to calculation of group mean and standard
deviation. Differences between group means were analyzed by
ANOVA test, with appropriate post tests. P value of 0.05 or less
was considered statistically significant. Values were means±
SE. The low numbers of ferrets per group (n=3 or 4) made
statistical calculations not significant in certain instances. In the
clinical chemistry and hematology studies, group means were
compared to baseline values as indicated in the text.
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